How to Choose a GLP-1 Provider as a Busy Mom

What the headline numbers actually came from

The figures that sell GLP-1 care come from two trials, worth reading before any advertisement. STEP 1 randomized 1,961 adults with overweight or obesity and no diabetes to once-weekly semaglutide 2.4 mg or placebo for 68 weeks — with a lifestyle intervention given to both arms¹. SURMOUNT-1 randomized 2,539 adults to tirzepatide 5, 10 or 15 mg or placebo for 72 weeks, including a 20-week dose-escalation period written into the protocol². Both trials' results are in the table below, placebo arm included.

Two things fall out of that — the only two the research can settle. The placebo arms are not zero, so part of what any program shows you is the lifestyle half of the trial, not the drug. And the escalation period is not a courtesy — it is protocol. A program offering to move you up faster than the trials did is not offering the trial's result; it is offering something nobody measured.

What the label requires of whoever prescribes it

This part is documented, not a matter of taste, and it is short.

A contraindication screen. The semaglutide boxed warning states the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)³. That is a family-history question, and an intake that never asks it has skipped a contraindication, not a preference. Our thyroid guide covers what that warning does and doesn't say.

A pregnancy-timing conversation. The Wegovy label instructs discontinuing the drug at least two months before a planned pregnancy, to account for semaglutide's long half-life³. The pharmacology behind that number: the elimination half-life is about one week, and semaglutide is still present in circulation for about five to seven weeks after the last dose³. Two months is a specific instruction, not a vibe — contraception belongs in the first appointment, not the fourth.

On nursing, the label is more nuanced than the internet suggests, and a provider who flattens it is guessing. For the injection, the label reports no data on semaglutide in human milk and asks that breastfeeding's benefits be weighed against the mother's clinical need. For the oral tablet, breastfeeding is not recommended during treatment — because of the SNAC absorption enhancer the tablet contains, which the injection does not³. We work through that distinction in what the label says about breastfeeding.

Monitoring your other prescriptions. The label notes semaglutide delays gastric emptying and can affect absorption of oral medications taken alongside it, and asks for increased monitoring of oral drugs with a narrow therapeutic index³. Levothyroxine is the everyday example for women, and the reason a thyroid dose and a GLP-1 start belong in the same conversation.

What the FDA says about the cheaper version

Cost is the real barrier for many mothers, and compounded semaglutide or tirzepatide is where that pressure lands. The FDA's position is specific rather than rhetorical: compounded drugs are not FDA approved, meaning the agency does not review them for safety, effectiveness or quality before marketing, and they should be used only when a patient's medical need can't be met by an approved drug⁴. The agency also says patients should obtain a prescription from their doctor and fill it at a state-licensed pharmacy⁴.

The same page publishes a telehealth red-flag list, worth more than any checklist we could invent, because it's the regulator's own. Watch for a company claiming a compounded drug matches an FDA-approved one; offering prices too good to be true; skipping screening and a doctor's prescription; having no doctor available afterward; or shipping medicine with a broken package, missing instructions, or an unverifiable pharmacy address⁴. The FDA separately notes that retatrutide and cagrilintide cannot lawfully be compounded at all, and has warned telehealth companies for marketing them⁴.

The first item on that list — a company claiming its compounded drug matches an FDA-approved one — sounds easy to catch, until it shows up on a provider's own page. Checked live in August 2026: Peter MD's GLP-1/B12 page headlines "delivers FDA-approved medication," while the body copy on the same page calls it "clinician-prescribed medication compounded with B12." Compounded GLP-1 isn't FDA-approved — the page contradicts itself.

The "too good to be true" line is worth sitting with. Zealthy carries one of the lowest disclosed prices we track, alongside an April 2026 federal receivership petition and a September 2025 FDA warning letter for unlawful sale of unapproved compounded semaglutide — a real answer to what the discount can cost. Henry Meds, priced well above it, publishes no exact number at all; the figure only appears inside its eligibility flow, its own kind of opacity.

The pharmacy red flag is the one item you can settle from a sofa, and the answers differ more than the marketing does. Checked against three sellers in July 2026: EverSlim names three pharmacies — footer, terms, and telehealth consent. Bionomy Health names two, and says it does so "because regulation is built on transparency", while omitting that the one it uses for GLP-1 fills has been on California Board of Pharmacy probation since 2023. Brightmeds names none in its own voice; the three named in its terms of use are a different company's pharmacy partners, because the contract published on its site is that company's document. None of that is visible from a homepage, and all of it took an afternoon.

The same check against three more, in August 2026: Oak does not name its compounding pharmacy anywhere public, and its founder is undisclosed — its BBB-listed address (Vancouver, BC) doesn't match its Delaware filing. yourEra publishes no pharmacy name either, alongside a "from" starting price that omits the ongoing, post-titration rate. SynergyRX names its prescribing physicians but not a pharmacy, and withholds its GLP-1 price until after a consultation — the too-good-or-too-opaque pattern the FDA's list warns about runs both directions. None of these is a safety finding alone; each is a box the FDA's checklist asks a reader to check, and none of the three checks it.

Two more checklist items rarely get checked: whether a prescriber is licensed in your state, and whether the quoted price is genuinely on the page. MadeMed is licensed in only 23 states, excluding California, Washington, Oregon and most of the country's biggest population centers; Wellorithm covers 49, excluding only Louisiana. Live Vital's GLP-1 pricing never appears in the page's visible HTML — it only renders from the site's own compiled JavaScript, the file a real browser loads. None of that is on the FDA's list, but "available everywhere" and "the price is right there" are both worth confirming.

Six more worked examples from this pass, in August 2026 — none a plug, none a warning by itself. Eve's real pricing only renders inside a separate signup subdomain, the same pattern Live Vital shows above. Framework names a real 503B pharmacy — genuine transparency — but publishes no state list at all. WePeptideRx pulled from its own data files, not its marketing shell, disclosed an exact 48-state list. Open Water Rx previously showed two conflicting semaglutide prices; re-checked live, one page states one number, and the lower figure is a promo code. Neo Soma Healthcare names a licensed physician but its footer still reads a stale 2023 copyright. Mevo Health names four real physicians, two of whom also appear on other DTC brands' sites.

Where this sits on the evidence scale

Mixed, and the split is the whole point of this page.

The requirements above are high-grade evidence in the most useful sense: a boxed warning, a two-month discontinuation instruction, and a monitoring instruction are documents you can hold a prescriber to. Behind them sit two large randomized, placebo-controlled trials — 1,961 and 2,539 adults — that tell you what a monitored, slowly titrated program actually produced, placebo arm included.

What has no evidence base at all is the ranking question underneath the search. Nobody has run a trial comparing telehealth GLP-1 programs against each other on weight outcomes, adherence, or safety; there is no research showing that any particular provider produces better results than another, and there is unlikely to be any soon, because nobody is funding it. Any page that implies otherwise — including this one, if it tried — would be describing marketing rather than data. So judge a program on whether it does the documented things: screens the contraindication, times the pregnancy question, monitors your other prescriptions, and is transparent about whether the drug it dispenses is an approved product. That is the part the evidence can settle. The rest is a preference, and it should be labeled as one.